American Society of Hirudotherapy

A Case Description of Spontaneous Intracardiac Thrombogenesis During Mitral Valve Repair: A Complication of Aminocaproic Acid?

Research article published in A&A practice (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportSafety & Infection ControlZavala et al. · A&A practice, 2025

Abstract

Bleeding is common after cardiac surgery and is associated with increased morbidity and mortality. The etiology of coagulopathy after cardiopulmonary bypass is complex, involving systemic inflammation, hemodilution, residual heparin effect, platelet activation, hypothermia, and hyperfibrinolysis. Antifibrinolytic agents such as aprotinin and lysine analogs are used to mitigate hyperfibrinolysis. Although epsilon-aminocaproic acid (EACA) is generally considered safe, dosing regimens vary, and thrombotic complications are underreported in national registries. We describe a case of acute intracardiac thrombosis shortly after EACA administration during mitral valve repair in a patient with no known hematologic or hypercoagulable conditions. .

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase Reports
Indexed MeSH termsHumansAminocaproic AcidAntifibrinolytic AgentsMitral ValveMitral Valve InsufficiencyThrombosis

Summary

Peer-reviewed research on safety and infection-control considerations relevant to leech therapy and anticoagulation. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This case report describes acute intracardiac thrombosis occurring shortly after epsilon-aminocaproic acid (EACA, an antifibrinolytic lysine analog) was given during mitral valve repair in a patient with no known hypercoagulable condition, set against the complex coagulopathy that follows cardiopulmonary bypass. Its connection to hirudotherapy is conceptual and centers on the hemostatic balance: leech salivary secretome works in the opposite direction, supplying antithrombotic and antiplatelet activity, so this report illustrates the thrombotic risk at the other end of the fibrinolysis spectrum that clinicians weigh when managing surgical bleeding versus clotting. Honest caveat: this is a single, hypothesis-generating case report (the authors themselves pose EACA as a question), it involves no leeches, and it cannot establish that EACA causes such thrombosis, only that the events were temporally associated.

Citation

A Case Description of Spontaneous Intracardiac Thrombogenesis During Mitral Valve Repair: A Complication of Aminocaproic Acid?.

Zavala et al. · A&A practice, 2025

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.